FollistatinvsSLU-PP-332

Follistatin is a naturally occurring monomeric glycoprotein produced by virtually all tissues, with particularly high expression in the liver, ovaries, and skeletal muscle. It functions as a high-affinity binding protein for several members of the TGF-beta superfamily, most importantly myostatin (GDF-8) and activin A/B. By binding these ligands with picomolar affinity, follistatin sequesters them in inactive complexes and prevents them from engaging their cell-surface receptors.

Myostatin is the primary endogenous negative regulator of skeletal muscle mass. It signals through the activin type IIB receptor (ActRIIB), which recruits and activates the type I receptor ALK4/5, initiating Smad2/3 phosphorylation. Phosphorylated Smad2/3 complexes with Smad4, translocates to the nucleus, and suppresses the expression of myogenic transcription factors MyoD, myogenin, and Myf5 — directly inhibiting satellite cell differentiation, muscle protein synthesis, and myofibrillar growth. By neutralizing myostatin, follistatin removes this molecular brake, allowing the myogenic program to proceed unchecked.

Follistatin exists in multiple isoforms with distinct tissue distributions. Follistatin 315 (FS315) contains a heparan sulfate proteoglycan-binding domain that anchors it to cell surfaces and local tissue, making it a paracrine factor. Follistatin 344 (FS344) lacks this anchoring domain and circulates freely in the bloodstream, acting as an endocrine factor. FS344 is the commercially available form and, upon injection, is cleaved to FS315 and FS303 in circulation. Beyond myostatin, follistatin's neutralization of activin has broader endocrine effects — activin is a critical stimulator of FSH production in the pituitary, which is why follistatin also functions as a reproductive hormone regulator. This multi-target activity means exogenous follistatin administration could potentially affect fertility and other TGF-beta-mediated processes.

SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.

SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.

The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.